We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Dimitra
Peppa
d.peppa@ucl.ac.uk
Dr
Dimitra
Peppa
d.peppa@ucl.ac.uk
Dr
Dimitra
Peppa
d.peppa@ucl.ac.uk
Human immunodeficiency virus [HIV] disease
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Human immunodeficiency virus type 1 (HIV-1) infection remains a major cause of mortality and morbidity worldwide. There is an ongoing need to better characterise and harness the immune response in order to develop effective prophylactic strategies and supplement current therapeutic approaches for a ‘functional’ HIV cure.
Virus-host interactions during primary HIV-1 infection (PHI) are crucial determinants of the entire subsequent disease course. Primary infection thus presents an ideal opportunity to study the evolution of the immune response and understand why the immune system fails to contain early virus replication more competently. In chronic infection immune responses become progressively more dysregulated/’exhausted’ and less adaptable. The precise mechanisms of this immune dysfunction/disarray, affecting virtually every arm of the immune response, remain incompletely understood.
Accumulating evidence indicates that in addition to the pivotal role of adaptive immunity, in particular T cells, in the control of HIV, innate cells, such as Natural Killer (NK) cells, make a significant contribution to containment of viral replication and shaping of adaptive immunity (and may influence disease progression). A better understanding of the complex virus-host interactions will allow us to identify the ideal targets for immune-based therapies and generation of protective vaccine-induced immune responses.
We aim to further dissect the detailed molecular pathways underpinning the failure of antiviral immunity in HIV-1 infection and identify the immunological and genetic determinants that give rise to enhanced and sustained virological control. This work has important implications for our efforts/ultimate goal to induce immunity through the design of prophylactic and therapeutic vaccines.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patients who meet any of the following criteria will be excluded: 1. Unable or unwilling to give informed consent 2. Co-infection with hepatitis B (surface antigen positive or detectable HBV Deoxyribonucleic acid (DNA) levels in blood) or Hepatitis C Virus Ribonucleic acid (HCV RNA positive) at the time of enrollment 3. Current acquired immune deficiency syndrome (AIDS) defining condition 4. Pregnant females
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Dimitra
Peppa
d.peppa@ucl.ac.uk
Dr
Dimitra
Peppa
d.peppa@ucl.ac.uk
Dr
Dimitra
Peppa
d.peppa@ucl.ac.uk
The study is sponsored by University College London and funded by Duke University (NC, USA); Medical Research Council (MRC); National Institute of Allergy and Infectious Diseases (NIH NIAID); .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 32753
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
